What’s the prognosis for MDS-related anemia? How is prognosis determined?
MDS experts, Dr Rafael Bejar and Dr Casey O’Connell, provide an overview of how prognosis (outlook) is determined in MDS. Risk scores are used to predict outlook and decide on treatment options. Your doctor will calculate your risk score based on which blood counts are low, your number of blasts, and any gene changes they see. They also describe the International Prognostic Scoring System (IPSS) and the Revised International Prognostic Scoring System (IPSS-R) tools that categorize risk, ranging from very low risk to very high risk. Lastly, the experts explain the various meanings of the term “risk” as it relates to MDS: risk of the MDS developing into acute myeloid leukemia (AML), as well as risk of overall survival (life expectancy with MDS).
Share with family and friends:
Click here to take our Myelodysplastic Syndromes (MDS) SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.
This educational activity has been developed by
the Myelodysplastic Syndromes Foundation, Inc and Mechanisms in Medicine Inc.
This activity is supported by an educational grant from Acceleron Pharma, Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.